Table 2 This table depicts the median age (min–max) and gender distribution for the MRONJ cases reported to the FAERS database for each of the twenty most commonly reported medications from 2010 to 2014 and from 2015 to 2021
2010 to 2014 | 2015 to 2021 | ||||
|---|---|---|---|---|---|
Medication: | Median Age (Min–Max) | % Female | Medication: | Median Age (Min–Max) | % Female |
1. Zoledronic Acid | 65 (26–113) | 59.7 | 1. Denosumab | 71 (18–104) | 65.3 |
2. Alendronate | 67 (30–102) | 89.8 | 2. Zoledronic Acid | 68 (23–98) | 59.8 |
3. Denosumab | 70 (24–113) | 57.3 | 3. Alendronate | 76 (44–97) | 89.3 |
4. Pamidronate | 65 (35–113) | 75.7 | 4. Ibandronate | 75 (42–100) | 93.5 |
5. Ibandronate | 65 (30–93) | 91.1 | 5. Lenalidomide | 70 (43–94) | 44.7 |
6. Lenalidomide | 64 (34–87) | 39.0 | 6. Pamidronate | 64 (39–89) | 67.0 |
7. Risedronate | 66 (40–85) | 91.4 | 7. Bevacizumab | 64 (39–80) | 72.8 |
8. Sunitinib | 61.5 (29–80) | 21.4 | 8. Prednisolone | 71 (22–91) | 55.3 |
9. Bevacizumab | 60 (21–74) | 62.0 | 9. Risedronate | 77 (47–95) | 90.1 |
10. Prednisone | 70 (34–89) | 50 | 10. Dexamethasone | 69 (46–90) | 38.4 |
11. Dexamethasone | 64 (34–84) | 45.7 | 11. Everolimus | 64.5 (29–82) | 27.8 |
12. Docetaxel | 63 (52–83) | 25 | 12. Sunitinib | 61 (33–85) | 20.5 |
13. Letrozole | 67 (46–84) | 100 | 13. Palbociclib | 65.5 (43–90) | 97.3 |
14. Methotrexate | 69 (52–84) | 93.3 | 14. Docetaxel | 68 (33–86) | 25.9 |
15. Everolimus | 63.5 (52–77) | 33.3 | 15. Methotrexate | 66 (34–88) | 70.6 |
16. Paclitaxel | 65 (56–73) | 88.9 | 16. Prednisone | 65 (35–91) | 63.8 |
17. Imatinib | 72 (62–76) | 75 | 17. Pomalidomide | 70 (48–83) | 48.3 |
18. Sorafenib | 65.5 (40–76) | 25 | 18. Radium 223 | 73 (61–86) | 0 |
19. Teriparatide | 72 (42–82) | 100 | 19. Nivolumab | 67 (22–79) | 13.0 |
20. Temsirolimus | 61 (49–70) | 33.3 | 20. Cabozantinib | 61 (40–79) | 27.3 |